Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD24Fc with Ipilimumab and Nivolumab in Melanoma
NCT04060407Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efprezimod alfa in melanoma, sponsored by Merck & Co.. Planned start Jun 2021; status: withdrawn.
02
Drugs
efprezimod alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04060407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060407.